U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468422) titled 'Organotypic Platform for Therapeutic Investigation (OPTin) for Guiding Cancer Patients Treatment' on Nov. 22, 2025.
Brief Summary: The goal of this clinical trial is to learn whether a new laboratory method called OPTin can help doctors select the most effective, personalized cancer therapies for patients with advanced or treatment-resistant tumors. The study will also learn about the safety and feasibility of using OPTin to guide treatment decisions across different cancer types.
The main questions it aims to answer are:
Does OPTin accurately identify which drugs or drug combinations work best for each patient's tumor?
Does OPT...